Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525357 | 0.88 | MAPK14 (0.58) | MAPK13MAPK14ABL1LCKKIT | |
| SCHEMBL3525483 | 0.87 | MAPK14 (0.53) | MAPK13MAPK14CYP2C9ABL1 | |
| SCHEMBL13546265 | 0.85 | MAPK14 (0.55) | MAPK13MAPK14CYP2C9ABL1 | |
| SCHEMBL3528000 | 0.83 | MAPK14 (0.56) | MAPK13MAPK14CYP2C9 | |
| SCHEMBL3529186 | 0.83 | MAPK14 (0.51) | MAPK13MAPK14CYP2C9 | |
| SCHEMBL3523505 | 0.82 | MAPK14 (0.62) | MAPK13MAPK14CYP2C9 | |
| SCHEMBL4221472 | 0.82 | MAPK13 (0.51) | MAPK13MAPK14CYP2C9ABL1LCK | |
| SCHEMBL3523606 | 0.82 | MAPK14 (0.62) | MAPK13MAPK14CYP2C9ABL1 | |
| SCHEMBL3523173 | 0.82 | MAPK14 (0.60) | MAPK13MAPK14CYP2C9ABL1 | |
| SCHEMBL4225095 | 0.81 | MAPK13 (0.53) | MAPK13MAPK14CYP2C9ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | MAPK7, CNKSR1, MAPK1 | MAPK13 19/4885MAPK14 11/4885CYP2C9 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.